Lilly to pay up to $1.5 billion for Calytrix, founded in 2025, before human trials
Calytrix, founded in 2025 by J.P. Morgan's life sciences venture arm, is developing a preclinical antibody for two rare blood cancers driven by mutant calreticulin. Its shareholders could receive up to $1.5 billion in cash.

- Value
- $1.5B
- Type
- Acquisition
- Target
- Calytrix Bio
- Buyer
- Eli Lilly and Company
- Sector
- Biotech
- Announced
- Nov. 16, 2026
Calytrix Bio was founded last year and has not yet tested its drug in people. Eli Lilly and Co. has agreed to pay as much as $1.5 billion for it.
Calytrix, of Wellesley Hills, Mass., said Nov. 16 that it signed a definitive agreement to be acquired by Lilly. Its shareholders could receive up to $1.5 billion in cash, made up of an upfront payment and later payments tied to clinical and regulatory milestones, the company said. Neither the upfront amount nor an expected closing date was disclosed.
Why it matters: Lilly is committing to a preclinical program aimed at a subset of patients with two blood cancers: those whose disease is driven by mutant calreticulin. Because the total includes milestone payments and the upfront amount was not disclosed, the $1.5 billion is a ceiling rather than what Lilly pays at closing.
The program
Calytrix develops treatments for myeloproliferative neoplasms, or MPNs, a group of blood cancers. Its lead asset is an investigational biparatopic antibody, meaning it binds two different sites, aimed at essential thrombocythemia and myelofibrosis driven by mutations in a gene called calreticulin, or CALR. The company said the antibody is designed to act on both Type 1 and Type 2 mutant CALR.
According to Calytrix, current drug therapies for the two diseases mainly manage symptoms and complications. The company said mutant CALR is a cell-surface target found only on the diseased cells, which it sees as a potential way to remove those cells while sparing normal tissue. The program has not yet entered clinical trials.
"Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms," said Brad Prosek, its president and chief executive. He said the deal would let Lilly take the program through the clinic.
The backers
J.P. Morgan Life Sciences Private Capital, the life sciences venture arm of J.P. Morgan Asset Management, founded Calytrix in 2025. The company launched with a Series A co-led by J.P. Morgan Life Sciences Private Capital and Westlake BioPartners, followed by a Series B led by Avoro Ventures. It did not disclose how much it raised in either round.
Centerview Partners is Calytrix's exclusive financial adviser and Goodwin Procter its legal counsel. Paul, Weiss, Rifkind, Wharton & Garrison is advising Lilly.
The larger picture
The announcement said the deal broadens Lilly's presence in the myeloproliferative neoplasm field and builds on its existing work in blood cancers. Earlier this month, Lilly was also among the new investors in the $133 million Series B of T-Therapeutics, a U.K. company developing T cell engagers.
Another drugmaker placed a blood cancer bet in October, when Merck KGaA agreed to acquire Silence Therapeutics for about $1.3 billion. That deal centers on a candidate for polycythemia vera, a rare blood cancer.
What comes next
The Calytrix announcement included no comment from Lilly and gave no timeline for the first human study or for the deal to close. Those, along with the size of the upfront payment, remain the open questions.



